Antidepressant Use in the Elderly Is Associated with an Increased Risk of Dementia

Alzheimer Disease and Associated Disorders

Volumn 30, Issue 2, 2016, Pages 99-104

  Wang, Chenkun ^a,d,h   Gao, Sujuan ^a,d,f   Hendrie, Hugh C ^b,e,f   Kesterson, Joe ^e   Campbell, Noll L ^e,f,g   Shekhar, Anantha ^b   Callahan, Christopher M ^c,e,f  

^a Division of Biostatistics   (United States)

^b Departments of Psychiatry   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

^f INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

^g PURDUE UNIVERSITY   (United States)

^h VERTEX PHARMACEUTICALS   (United States)

Author keywords

antidepressants; dementia; retrospective cohort study

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; MAJOR DEPRESSION; MASS SCREENING; PROCEDURES; RISK FACTOR;

AGED; ANTIDEPRESSIVE AGENTS; DEMENTIA; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MASS SCREENING; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 84944348203     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000103     Document Type: Article

References (40)

1. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999; 174:307-311.
2. McDougall FA, Matthews FE, Kvaal K, et al. Prevalence and symptomatology of depression in older people living in institutions in England and Wales. Age Ageing. 2007;36:562-568.
3. Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. Clin Geriatr Med. 2003;19:663-696. v.
4. Lindsley CW. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci. 2012;3:630-631.
5. Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry. 2006;59:1136-1143.
6. Banasr M, Duman RS. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets. 2007;6:311-320.
7. Schmitt JA, Wingen M, Ramaekers JG, et al. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12: 2473-2486.
8. Mowla A, Mosavinasab M, Haghshenas H, et al. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? - a doubleblind, placebo-controlled clinical trial. J Clin Psychopharm. 2007;27:484-487.
9. Giron MST, Forsell Y, Bernsten C, et al. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psych. 2001;16:900-906.
10. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry. 1999;60(suppl 20):4-8.
11. Kessing LV, Sondergard L, Forman JL, et al. Antidepressants and dementia. J Affect Disorders. 2009;117:24-29.
12. Goveas JS, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study. Int Psychogeriatr. 2012;24:1252-1264.
13. Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. 2011;26:316-322.
14. Callahan CM, Hui SL, Nienaber NA, et al. Longitudinal study of depression and health services use among elderly primary care patients. J Am Geriatr Soc. 1994;42:833-838.
15. Callahan CM, Hendrie HC, Dittus RS, et al. Improving treatment of late life depression in primary care: a randomized clinical trial. J Am Geriatr Soc. 1994;42:839-846.
16. McDonald CJ, Tierney WM, Overhage JM, et al. The Regenstrief Medical Record System: 20 years of experience in hospitals, clinics, and neighborhood health centers. MD Comput. 1992;9:206-217.
17. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
18. Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329-335.
19. Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236re4.
20. Vermetten E, Vythilingam M, Southwick SM, et al. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry. 2003;54:693-702.
21. Czeh B, Michaelis T, Watanabe T, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA. 2001;98:12796-12801.
22. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
23. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA. 2003;100:1387-1392.
24. Geerlings MI, Brickman AM, Schupf N, et al. Depressive symptoms, antidepressant use, and brain volumes on MRI in a population-based cohort of old persons without dementia. J Alzheimers Dis. 2012;30:75-82.
25. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-691.
26. Lebedev AV, Beyer MK, Fritze F, et al. Cortical changes associated with depression in Alzheimer's disease: an Mri surface-based morphometric study. Am J Geriatr Psychiatry. 2014;22:4-13.
27. Mlyniec K, Nowak G. GPR39 up-regulation after selective antidepressants. Neurochem Int. 2013;62:936-939.
28. Craddock TJ, Tuszynski JA, Chopra D, et al. The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One. 2012;7:e33552.
29. Rulon LL, Robertson JD, Lovell MA, et al. Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res. 2000;75:79-85.
30. Dodd S, Horgan D, Malhi GS, et al. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord. 2005;89:1-11.
31. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
32. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31:945-961.
33. Richard E, Reitz C, Honig LH, et al. Late-life depression, mild cognitive impairment, and dementia. Jama Neurol. 2013;70: 383-389.
34. St Germaine-Smith C, Metcalfe A, Pringsheim T, et al. Recommendations for optimal Icd codes to study neurological conditions: a systematic review. Am J Epidemiol. 2012;175: S126-S126.
35. Taylor DH, Ostbye T, Langa KM, et al. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17:807-815.
36. Callahan CM, Arling G, Tu WZ, et al. Transitions in care for older adults with and without dementia. J Am Geriatr Soc. 2012;60:813-820.
37. Hendrie HC, Tu WZ, Tabbey R, et al. Health outcomes and cost of care among older adults with schizophrenia: a 10-year study using medical records across the continuum of care. Am J Geriat Psychiatry. 2014;22:427-436.
38. Bynum JPW, Rabins PV, Weller W, et al. The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use. J Am Geriatr Soc. 2004;52:187-194.
39. Murphy E, Hou L, Maher BS, et al. Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacology. 2013;38:2598-2606.
40. Reinlieb ME, Persaud A, Singh D, et al. Vascular depression: overrepresented among African Americans? Int J Geriatr Psychiatry. 2014;29:470-477.